Living With T1D/September 10, 2026/2 min read

Automated Insulin Delivery: What a Long-Term Economic Model Projects

Researchers used one year of real-world data to model possible long-term health and cost outcomes. The 55-year horizon is a simulation, not decades of observed follow-up.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

This is an economic modeling study, not a 55-year clinical follow-up study.
The model used data from an England pilot involving 251 children and adolescents, including changes observed during the first year of system use.
Long-term complication rates, quality-adjusted life years and costs were projected using assumptions and country-specific inputs.
The projections do not establish an individual outcome or prove that the modeled long-term benefits have already occurred.

What the researchers modeled

Researchers used the IQVIA Core Diabetes Model to compare automated insulin delivery with multiple daily injections plus continuous glucose monitoring. They modeled health and economic outcomes over a 55-year horizon for Australia, Canada, the United Kingdom and the United States.

What was observed and what was projected

The clinical inputs came from an NHS England pilot involving 251 children and adolescents, with changes observed during the first year of automated insulin-delivery use. The long-term complication rates, quality-adjusted life years and cost estimates came from the model. They were not outcomes measured after following those participants for 55 years.

How to interpret the findings

The authors projected improved long-term health outcomes and cost-effectiveness under their model assumptions. Those estimates depend on how short-term changes are carried forward, the complication-risk equations, country-specific costs and discount rates. A model can support planning; it cannot establish that its predicted benefits have already happened or forecast a particular person’s outcome.

Limits of this summary

This summary uses the indexed abstract. It does not independently validate the model or reproduce a full sensitivity analysis. The economic findings should not be presented as a trial proving a specific treatment benefit, a guarantee of cost savings or advice to change diabetes care.

Evidence label

Economic modeling study using real-world clinical inputs. Source: Diabetes Technology & Therapeutics, PMID 42719944. Type1Cure provides information, not personal medical advice.

Editorial correction

Distinguished observed first-year inputs from 55-year modeled projections; removed unsupported causal, guaranteed-benefit and cost-saving language.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.